

**London, 3 February 2026** - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its financial results for the year ended 31 December 2025 on Thursday 26 February 2026.

A recording of the presentation and slide deck will be available on the Group's website at [www.hikma.com](http://www.hikma.com) from 7:00am GMT. Hikma will also hold a live Q&A call for analysts at 9:30am GMT, and a recording will be made available on the website.

Please use the following link to register for the webinar:

<https://sparklive.lseg.com/HikmaPharmaceuticals/events/8e44521c-bdea-40c6-bffe-52aa5b6c780f>

- ENDS -

## Enquiries

### Hikma Pharmaceuticals PLC

Susan Ringdal  
EVP, Strategic Planning and Global Affairs  
Guy Featherstone  
Director, Investor Relations

+44 (0)20 7399 2760/ +44 (0)7776 477050

+44 (0)20 3892 4389/ +44 (0)7795 896738

### About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,300 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORMZGGZMZVGVZM